Tocilizumab mAb-based ELISA precisely measures free Tocilizumab in serum and plasma samples.

• Dynamic Range: 6 - 200 ng/mL
• Sensitivity: 2 ng/mL
• Incubation: 2.5 hours

The drug Tocilizumab (trade name Actemra®) is a humanized monoclonal antibody (mAb) that specifically targets both soluble interleukin-6 receptor (sIL-6R) and membrane bound interleukin-6 receptor (mIL-6R) with high affinity, thereby preventing pro-inflammatory effects of IL-6. The specificity of this testsystem is achieved by using a monoclonal antibody (clon IG-7C84) for the coating of the microtiter plate and also as a conjugate. This Eagle Biosciences Tocilizumab ELISA (mAb-based) is developed for the specific measurement of Tocilizumab in sera, plasma and other biological fluids by the advantage of using a site-directed IG-7C84 mouse monoclonal antibody (mAb) specific for Tocilizumab only. Binding of Tocilizumab to the solid phase, pre-coated with IG-7C84, is inhibited by recombinant human interleukin-6 receptor alpha (rh-IL6Ra) in a concentration dependent manner. Therefore, this Tocilizumab ELISA (mAb-Based) measures the free form of Tocilizumab. The choice of specifically measuring the free form allows investigators to analyze the concentration-effect relationship. Due to the use of a mAb as catcher and also as detection reagent this testkit has an unmatched specificty.